Citation Impact 2023
Journal Impact Factor: 3.7
5-year Journal Impact Factor: 4.6
Source Normalized Impact per Paper (SNIP): 0.960
SCImago Journal Rank (SJR): 1.048
Speed 2023
Submission to first editorial decision (median days): 8
Submission to acceptance (median days): 76
Usage 2023
Downloads: 435,217
Altmetric mentions: 154
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
HER3 is the third member of the human epidermal growth factor receptor (HER/EGFR) family, and unlike its other family members, is unique due to its minimal intrinsic kinase activity. As a result, HER3 has to i...